• John-Paul Taylor, Ian G McKeith, David J Burn, Brad F Boeve, Daniel Weintraub, Claire Bamford, Louise M Allan, Alan J Thomas, and John T O'Brien.
• Institute of Neuroscience, Biomedical Research Building, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK. Electronic address: john-paul.taylor@ncl.ac.uk.
• Lancet Neurol. 2020 Feb 1; 19 (2): 157169157-169.

AbstractDementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia, are common neurodegenerative conditions. Patients with Lewy body dementia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. Presentation varies between patients and can vary over time within an individual. Treatments can address one symptom but worsen another, which makes disease management difficult. Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish. Clinical trials and meta-analyses now provide an evidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Lewy body dementia. Furthermore, consensus opinion from experts supports the application of treatments for related conditions, such as Parkinson's disease, for the management of common symptoms (eg, autonomic dysfunction) in patients with Lewy body dementia. However, evidence gaps remain and future clinical trials need to focus on the treatment of symptoms specific to patients with Lewy body dementia.Copyright © 2020 Elsevier Ltd. All rights reserved.

14 keywords...

hide…